Population impact and cost-effectiveness of artificial intelligence-based diabetic retinopathy screening in people living with diabetes in Australia: a cost effectiveness analysis

被引:8
|
作者
Hu, Wenyi [1 ,2 ]
Joseph, Sanil [1 ,2 ]
Li, Rui [4 ,5 ,9 ]
Woods, Ekaterina [1 ,2 ]
Sun, Jason [6 ]
Shen, Mingwang [9 ]
Jan, Catherine Lingxue [1 ,2 ]
Zhu, Zhuoting [1 ,2 ,11 ]
He, Mingguang [1 ,2 ,7 ,8 ,11 ]
Zhang, Lei [1 ,3 ,4 ,5 ,10 ]
机构
[1] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia
[2] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Australia
[3] Nanjing Med Univ, Clin Med Res Ctr, Childrens Hosp, Nanjing 210008, Jiangsu Provinc, Peoples R China
[4] Monash Univ, Fac Med, Cent Clin Sch, Melbourne, Vic, Australia
[5] Alfred Hlth, Melbourne Sexual Hlth Ctr, Artificial Intelligence & Modelling Epidemiol Prog, Melbourne, Vic, Australia
[6] Eyetelligence Pty Ltd, Melbourne, Australia
[7] Hong Kong Polytech Univ, Sch Optometry, Hong Kong, Peoples R China
[8] Hong Kong Polytech Univ, Res Ctr SHARP Vis, Hong Kong, Peoples R China
[9] Xi An Jiao Tong Univ, China Australia Joint Res Ctr Infect Dis, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China
[10] 2 Guangzhou Rd, Nanjing 210008, Jiangsu Provinc, Peoples R China
[11] Level 7-32 Gisborne St, East Melbourne, Vic 3002, Australia
基金
英国医学研究理事会;
关键词
Cost-effectiveness; Artificial intelligence; Diabetic retinopathy; Screening; RETINAL PHOTOGRAPHY; PREVALENCE; PROGRAM; MORTALITY; ADHERENCE; COHORT;
D O I
10.1016/j.eclinm.2023.102387
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We aimed to evaluate the cost-effectiveness of an artificial intelligence -(AI) based diabetic retinopathy (DR) screening system in the primary care setting for both non -Indigenous and Indigenous people living with diabetes in Australia. Methods We performed a cost-effectiveness analysis between January 01, 2022 and August 01, 2023. A decisionanalytic Markov model was constructed to simulate DR progression in a population of 1,197,818 non -Indigenous and 65,160 Indigenous Australians living with diabetes aged >= 20 years over 40 years. From a healthcare provider's perspective, we compared current practice to three primary care AI -based screening scenarios-(A) substitution of current manual grading, (B) scaling up to patient acceptance level, and (C) achieving universal screening. Study results were presented as incremental cost-effectiveness ratio (ICER), benefit -cost ratio (BCR), and net monetary benefits (NMB). A Willingness -to -pay (WTP) threshold of AU$50,000 per quality -adjusted life year (QALY) and a discount rate of 3.5% were adopted in this study. Findings With the status quo, the non -Indigenous diabetic population was projected to develop 96,269 blindness cases, resulting in AU$13,039.6 m spending on DR screening and treatment during 2020-2060. In comparison, all three intervention scenarios were effective and cost -saving. In particular, if a universal screening program was to be implemented (Scenario C), it would prevent 38,347 blindness cases, gain 172,090 QALYs and save AU$595.8 m, leading to a BCR of 3.96 and NMB of AU$9,200 m. Similar findings were also reported in the Indigenous population. With the status quo, 3,396 Indigenous individuals would develop blindness, which would cost the health system AU$796.0 m during 2020-2060. All three intervention scenarios were cost -saving for the Indigenous population. Notably, universal AI -based DR screening (Scenario C) would prevent 1,211 blindness cases and gain 9,800 QALYs in the Indigenous population, leading to a saving of AU$19.2 m with a BCR of 1.62 and NMB of AU$509 m. Interpretation Our findings suggest that implementing AI -based DR screening in primary care is highly effective and cost -saving in both Indigenous and non -Indigenous populations. Copyright (c) 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review
    Avidor, Daniel
    Loewenstein, Anat
    Waisbourd, Michael
    Nutman, Amir
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
  • [42] Impact on blindness of organized diabetic retinopathy screening including artificial intelligence (AI) and optical coherence tomography (OCT) in urban China - a lifetime cost-effectiveness analysis (CEA)
    Harding, Simon
    Wang, Zhicheng
    So, Ching
    Chen, Xiuju
    McGhee, Sarah
    Li, Xiaoxin
    Wong, David
    Lian, Jinxiao
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [43] Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review
    Daniel Avidor
    Anat Loewenstein
    Michael Waisbourd
    Amir Nutman
    Cost Effectiveness and Resource Allocation, 18
  • [44] The Cost-Effectiveness of a Telemedicine Screening Program for Diabetic Retinopathy in New York City
    Muqri, Hasan
    Shrivastava, Anurag
    Muhtadi, Rakin
    Chuck, Roy S.
    Mian, Umar K.
    CLINICAL OPHTHALMOLOGY, 2022, 16 : 1505 - 1512
  • [45] Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia
    Barbara de Graaff
    Amanda Neil
    Lei Si
    Kwang Chien Yee
    Kristy Sanderson
    Lyle Gurrin
    Andrew J. Palmer
    Applied Health Economics and Health Policy, 2017, 15 : 521 - 534
  • [46] Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia
    de Graaff, Barbara
    Neil, Amanda
    Si, Lei
    Yee, Kwang Chien
    Sanderson, Kristy
    Gurrin, Lyle
    Palmer, Andrew J.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (04) : 521 - 534
  • [47] COST-EFFECTIVENESS OF STRATEGIES FOR DETECTING DIABETIC-RETINOPATHY
    DASBACH, EJ
    FRYBACK, DG
    NEWCOMB, PA
    KLEIN, R
    KLEIN, BEK
    MEDICAL CARE, 1991, 29 (01) : 20 - 39
  • [48] A Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy
    Patel, Nimesh A.
    Yannuzzi, Nicolas A.
    Lin, James
    Smiddy, William E.
    OPHTHALMOLOGY RETINA, 2022, 6 (03): : 213 - 218
  • [49] Cost-effectiveness of screening for hydroxychloroquine retinopathy - optimization of the guideline
    van Asten, Freekje
    Quist, Sara W.
    te Dorsthorst, Sophie
    Freriks, Roel D.
    Postma, Maarten J.
    Hoyng, Carel C. B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [50] Cost-Effectiveness and Cost-Utility of Artificial Intelligence-Assisted Population Screening for Glaucoma in Australia: A Decision-Analytic Markov Model Approach
    Jan, Catherine
    Hu, Wenyi
    Vingrys, Algis J.
    van Wijngaarden, Peter
    Stafford, Randall S.
    He, Mingguang
    Zhang, Lei
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)